89bio — Investor Presentation (April 2020)
40 slides from 89bio's investor presentation, Apr 13, 2020
Slide 1: Developing a Differentiated FGF21 for NASH and SHTG
Developing a Differentiated FGF21 for NASH and SHTG April 2020 NASDAQ: ETNB Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of his
Slide 3: 89bio – Investment Highlights
89bio – Investment Highlights Targeting large and growing unmet need in Non-Alcoholic Steatohepatitis (NASH) and Severe Hypertriglyceridemia (SHTG) Significant Commercial Opportunities BIO89-100 is a glycoPEGylated analog of FGF21 with compelling early human data FGF21 has the potential to become ma
Slide 4: Opportunity in NASH
89 OPPORTUNITY IN NASH
Slide 5: BIO89-100 is A Compelling Drug Candidate in NASH
BIO89-100 is A Compelling Drug Candidate in NASH BIO89-100 HAS THE POTENTIAL TO BE A DIFFERENTIATED FGF21 ANALOG Robust clinical and preclinical data with an upcoming Anticipated efficacy readout Proprietary glycoPEGylation technology may offer robust biologic effects, favorable tolerability profile
Slide 6: NASH is A Serious Liver Condition With No FDA Approved Treatments
NASH is A Serious Liver Condition With No FDA Approved Treatments 16.5 million projected to grow to 27 million by 2030 Expected to become the leading cause of liver transplant in 2020 Significant economic burden – $223 billion expected lifetime economic burden of patients in US (2017) Co-morbidity P
Slide 7: Key Attributes for Successful NASH Therapies
Key Attributes for Successful NASH Therapies NASH Therapeutics - Market Dynamics Similarities to multi-billion diabetes and dyslipidemia markets Potent injectables have the potential to be a preferred treatment option for some patient populations (e.g. GLP-1 agonists achieved ~$9 billion in sales in
Slide 8: FGF21 product candidates deliver on key attributes for NASH therapies
FGF21 FGF19 FXR PPAR* THR-β GLP-1 Liver fat reduction ✔ ✔ ✔ ✔ ? Fibrosis improvement ✔ ✔ ✔ ? ? Triglyceride reduction ✔ ✔ ✔ ✔ LDL-C improvement ✔ Worsens LDL Worsens LDL ✔ ✔ HDL-C improvement ✔ ✔ Glucose reduction ✔ ✔ ✔ Limited Side Effects ✔ LDL ↑ Pruritis LDL ↑ Risk of renal toxicity; Hepatitis Dr
Slide 9: FGF21 Has Potential To Be Mainstay of Therapy in NASH
Endogenous metabolic hormone that regulates energy expenditure and glucose and lipid metabolism Activates FGF receptors 1c, 2c, 3c, not believed to activate receptor 4 (leads to increased LDL) Signaling requires co-activation of beta-klotho receptor Native FGF21 has a short half-life of < 2 hrs á Li
Slide 10: FGF21 – Clinically Validated in NASH
Pegbelfermin Absolute Change in % Liver Fat Fraction (Week 16) FGF21 – Clinically Validated in NASH Results from Pegbelfermin’s (BMS) and AKR-001’s (Akero) Phase 2a Studies 10 mg QD (N=23) 20 mg QW (N=22) Placebo (N=25) AKR-001 Absolute Reduction in % Liver Fat (Mean Change from Baseline to Week 12)
Slide 11: FGF19 – Additional Validation of FGF Class
22% of aldafermin (1mg QD) vs. 0% placebo patients achieved composite endpoint of fibrosis improvement and NASH resolution - statistically significant at week 24 39% reduction in absolute liver fat content at 24 weeks by MRI-PDFF in aldafermin patients; 38% of patients (versus 18% of placebo) had fi
Slide 12: BIO89-100 Is A Long Acting glycoPEGylated FGF21 Analog
BIO89-100 Is A Long Acting glycoPEGylated FGF21 Analog LONG Half-life (55-100 hours) MAY SUPPORT WEEKLY OR EVERY 2-WEEK DOSING Technology TO IMPROVE CLINICAL PROFILE Site-specific glycoPEGylation technology designed to prevent degradation, extend half-life, minimize potential for aggregation and ret
Slide 13: Preclinical Data Confirms BIO89-100's Mechanism of Action
12 Preclinical Data Confirms BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism CONFIDENTIAL BIO89-100 demonstrated low nanomolar potency against FGF Receptors 1c, 2c and 3c but not 4c similar to recombinant human FGF21 BIO89-100 has the potential to reproduce the beneficial metabolic e
Slide 14: Strong Preclinical Data with BIO89-100
Strong Preclinical Data with BIO89-100 Preclinical Pharmacology Study with BIO89-100 Reduced Hepatocyte Injury Reduced Liver Steatosis, Inflammation & Fibrosis Improved Lipid Handling* Improved Insulin Sensitivity Body Weight Reduction DIN mouse model (10 weeks) ✔ ✔ ✔ ✔ ✔ DIN mouse model (19 weeks)
Slide 15: Reduction in Steatosis, Inflammation, Fibrosis and NAS in DIN Model
Note : Obeticholic acid, 25 mg/kg tested as active control – did not separate from control in this study Scoring system: Steatosis (0-3), Inflammation (0-3), Fibrosis (0-4), NAS (0-13) - all were assessed at week 19; mean scores *** *** Vehicle BIO89-100, 0.02 mg/kg BIO89-100, 0.1 mg/kg BIO89-100, 0
Slide 16: Reduction in Body Weight and Triglycerides in Diabetic Obese Monkeys
Triglycerides (Mean % Change) (Baseline: 305 mg/dL) Dosing Baseline -14 -7 0 7 14 21 28 10 -40 -90 Significant Reduction in Body Weight and Triglycerides in Diabetic Obese Monkeys With Once Every 2 Weeks Dosing Baseline Dosing Body Weight (Mean % Change) (Baseline: 8.4kg) 4 0 -4 -8 -12 Days -14 -7 0
Slide 17: BIO89-100 Demonstrated a Favorable Clinical Profile in Phase 1a Study
BIO89-100 Demonstrated a Favorable Clinical Profile in Phase 1a Study Well tolerated Most commonly observed treatment related AEs (in > 2 subjects) were injection site reaction and headache, all of which were reported as mild PK was dose proportional; half-life of 55–100 hours Significant improvemen
Slide 18: Improvement in Triglycerides Following a Single Dose
Robust and Durable Improvement in Triglycerides Following a Single Dose of BIO89-100 * * * * * * * Mean Percentage Change at Day 8 from Baseline in Triglycerides (%) Mean Percentage Change at Day 15 from Baseline in Triglycerides (%) * 95% CI exclude 0% change from baseline Dose (mg) Placebo 0.45mg
Slide 19: Rapid and Durable Improvement in Triglycerides Following a Single Dose
Mean Percentage Change from Baseline in Triglycerides (%) Days * 95% CI exclude 0% change from baseline * * * * * * * * * * * * * * * * Rapid and Durable Improvement in Triglycerides Following a Single Dose of BIO89-100 CONFIDENTIAL
Slide 20: Improvement in LDL Cholesterol Following a Single Dose
Robust and Durable Improvement in LDL Cholesterol Following a Single Dose of BIO89-100 * * * * * * Dose (mg) Placebo 0.45mg 1.2mg 3mg 9.1mg 18.2mg 39mg 78mg N 15 6 6 6 7 6 6 6 Baseline 129.6 97.8 122 123.3 120.3 122.8 138.8 130.3 * 95% CI exclude 0% change from baseline CONFIDENTIAL
Slide 21: Changes in HDL Cholesterol Following a Single Dose
Robust and Durable Changes in HDL Cholesterol Following a Single Dose of BIO89-100 * * * * * * * * * Dose (mg) Placebo 0.45 mg 1.2 mg 3 mg 9.1 mg 18.2 mg 39 mg 78 mg N 15 6 6 6 7 6 6 6 Baseline 50.8 44.5 50 48.5 51 44.8 44.2 42.7 * 95% CI exclude 0% change from baseline CONFIDENTIAL
Slide 22: FGF21 Class - Pegbelfermin and AKR-001
FGF21 Class - Pegbelfermin and AKR-001 Pegylated molecule with moderate half-life of 19-24 hours–dosed daily and weekly Mutations with non-native amino acid substitutions Efficacy was lower when dosed weekly versus daily across key lipid measures in Phase 1 and 2a trials Fusion Protein molecule with
Slide 23: BIO89-100: Phase 1b/2a Study
BIO89-100: Phase 1b/2a Study Design: Randomized, double-blind, placebo-controlled Population: NASH or NAFLD patients with high risk of NASH* Dosing: Weekly or every 2 weeks regimen; six dosing cohorts: 3mg QW to 36mg Q2W Duration: 12 weeks Size/Power: n=81** patients enrolled; powered to show statis
Slide 24: Opportunity in SHTG
89 OPPORTUNITY IN SHTG
Slide 25: BIO89-100: A Compelling Drug Candidate For SHTG
BIO89-100: A Compelling Drug Candidate For SHTG Showed significant reduction in triglycerides in preclinical and clinical studies (up to 78% in monkey study and up to 51% after a single human dose) Potential for use as monotherapy or in combination with existing drugs or those in development Large p
Slide 26: SHTG Market Opportunity
SHTG Market Opportunity Large Patient Population… …With Large Unmet Need Increasing awareness of the importance of treating elevated TGs Residual CV risk despite effective LDL treatments with statins Outcome study (REDUCE-IT) demonstrated that reducing TG can significantly lower CV events Diagnosis
Slide 27: Key Attributes for Successful SHTG Therapies
Key Attributes for Successful SHTG Therapies SHTG Therapeutics – Key Attributes Robust TG reduction Address multiple co-morbidities of patients (dyslipidemia and insulin resistance) Need to have favorable benefit/risk profile Support compliance with effective dosing CONFIDENTIAL
Slide 28: BIO89-100 Potential to Deliver on Key Attributes for SHTG Therapy
FISH OILS FIBRATES FGF21 Analogs Vascepa (EPA) Epanova (EPA+DHA) Lovaza (EPA+DHA) Tricor LDL-C Improvement - Worsens LDL Worsens LDL Worsens LDL ✔ HDL-C Improvement - - - - ✔ Effect on other metabolic co-morbidities (liver fat, glycemic control) - - - - ✔ Tolerability/ Safety May prolong bleeding ti
Slide 29: Potent and Durable Reduction in Triglycerides with BIO89-100
Potent and Durable Reduction in Triglycerides Observed with BIO89-100 Baseline Dosing Days -14 -7 100 50 0 -50 -100 0 7 14 21 28 35 42 49 ** ** ** Triglycerides (% Change) (Baseline: 253mg/dL) * * * * Mean Percentage Change at Day 8 from Baseline in Triglycerides (%) Data from study in SAD in health
Slide 30: SHTG Clinical and Regulatory Path is Defined
Study Design Phase 2 Study* Adults with TG ≥ 500 on no background TG lowering therapy or on stable dose of statin and/or prescription fish oil; N = ~90 Multiple doses vs placebo Primary endpoint: Reduction from baseline in TG Secondary endpoints: Other lipids, hsCRP, glucose, body weight, safety, PK
Slide 31: Financial Position Summary
Financial Position Summary Completed successful upsized IPO on November 13, 2019 Raised gross proceeds of $97.6 million Priced within range at $16.00/share Cash Position $93.3 million (as of March 31, 2020); On April 7, 2020, 89bio entered into a debt facility with Silicon Valley Bank for a tranched
Slide 32: Recent and Upcoming Anticipated Clinical Milestones
Recent and Upcoming Anticipated Clinical Milestones BIO89-100 in NASH: BIO89-100 in SHTG: 2020 2021 1H 2H 1H 2H Topline data from Phase 1b/2a study Initiation of Phase 2b study Initiation of Phase 2 subject to conducive external environment* * Delayed due to the COVID-19 pandemic; Study designs and
Slide 33: Management Team
CEO, CCO experience Avanir, Medivation, J&J Commercial, strategy, and R&D experience Management Team 20 years of operations, BD, and strategy experience VP of strategy and transformation, Teva R&D VP of business development, XTL bio Rohan Palekar, CEO Ram Waisbourd COO and CBO Hank Mansbach, MD CMO
Slide 34: 89bio – Investment Highlights
89bio – Investment Highlights Targeting large and growing unmet need in Non-Alcoholic Steatohepatitis (NASH) and Severe Hypertriglyceridemia (SHTG) Significant Commercial Opportunities BIO89-100 is a glycoPEGylated analog of FGF21 with compelling early human data FGF21 has the potential to become ma
Slide 35: Appendix
89 APPENDIX
Slide 36: Reduction in Triglycerides and ALT in 8-Week Diabetic Obese Monkey Study
Significant Reduction in Triglycerides and ALT with BIO89-100 in 8-Week Diabetic Obese Monkey Study Baseline Dosing -14 -7 100 50 0 -50 -100 0 7 14 21 28 35 42 49 ** ** ** Triglycerides (Mean % Change) (Baseline: 253 mg/dL) 78% *p<0.05, **p<0.01 (compared to baseline) ALT (Mean % Change) (Baseline:
Slide 37: Changes in Adiponectin and HbA1c in Diabetic Obese Monkeys
HbA1c (Mean % Change) (Baseline: 9.7%) Dosing Baseline 20 0 -20 -40 -14 -7 0 7 14 21 28 Days 33% ** ** ** ─●─ Vehicle weekly ─●─ BIO89-100, 1.0mg/kg, weekly ─●─ BIO89-100, 1.0mg/kg once every 2 weeks ─●─ BIO89-100, 2.0mg/kg once every 2 weeks Significant Changes in Adiponectin and HbA1c in Diabetic
Slide 38: Reduction in Liver Cholesterol, Triglycerides and Fatty Acids in DIN Model
Liver total cholesterol (µg/mg liver) Liver triglycerides (µg/mg liver) Liver fatty acids (nmol/mg liver) Note: Obeticholic acid, 25 mg/kg tested as active control – did not separate from control in this study; data presented are mean values Vehicle BIO89-100, 0.02 mg/kg BIO89-100, 0.1 mg/kg BIO89-1
Slide 39: Improvement in Inflammatory and Fibrotic Markers in DIN Model
Improvement in Inflammatory and Fibrotic Markers with BIO89-100 in DIN Model Vehicle BIO89-100, 0.02 mg/kg BIO89-100, 0.1 mg/kg BIO89-100, 0.5 mg/kg *p<0.05, **p<0.01, ***p<0.001 *** ** * * Note: Obeticholic acid, 25 mg/kg tested as active control – did not separate from control in this study; data
Slide 40: Dosing Preference Study: T2D Patients Prefer Every Other Week Injections
Dosing Preference Study: >60% of T2D Patients Prefer or Strongly Prefer Every Other Week Injections 68% Prefer or Strongly Prefer 63% Prefer or Strongly Prefer Preference of Every Other Week Injections Over Daily Injections Preference of Every Other Week Injections Over Weekly Injections Study condu